Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9086129rdf:typepubmed:Citationlld:pubmed
pubmed-article:9086129lifeskim:mentionsumls-concept:C0019693lld:lifeskim
pubmed-article:9086129lifeskim:mentionsumls-concept:C0337810lld:lifeskim
pubmed-article:9086129lifeskim:mentionsumls-concept:C0039215lld:lifeskim
pubmed-article:9086129lifeskim:mentionsumls-concept:C0205246lld:lifeskim
pubmed-article:9086129lifeskim:mentionsumls-concept:C0678536lld:lifeskim
pubmed-article:9086129lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:9086129lifeskim:mentionsumls-concept:C0332120lld:lifeskim
pubmed-article:9086129pubmed:issue4lld:pubmed
pubmed-article:9086129pubmed:dateCreated1997-4-17lld:pubmed
pubmed-article:9086129pubmed:abstractTextIt has been suggested that the rate of CD4 cell decline accelerates in parallel with decreasing numbers of cells; however, the statistical literature suggests the opposite. CD4 cells were counted about every 6 months in a cohort of 1264 human immunodeficiency virus-infected subjects (the Italian Seroconversion Study cohort). Kaplan-Meier analysis was used to estimate the time for CD4 cells to decline by 100 cells/mm3, conditional on reaching predefined levels. In addition, CD4 cell counts were modeled as a function of time since seroconversion in individuals with > or = 5 counts. Kaplan-Meier survival times for a 100 cell/mm3 decrease in CD4 cells increased as lower counts were reached (log rank test, P < .001). The shape of the overall fitted curve of the CD4 cell counts does not suggest an increasing rate of decline. Data from the Italian Seroconversion Study cohort do not show a general tendency for accelerating CD4 cell decline in association with lower counts.lld:pubmed
pubmed-article:9086129pubmed:languageenglld:pubmed
pubmed-article:9086129pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9086129pubmed:citationSubsetAIMlld:pubmed
pubmed-article:9086129pubmed:statusMEDLINElld:pubmed
pubmed-article:9086129pubmed:monthAprlld:pubmed
pubmed-article:9086129pubmed:issn0022-1899lld:pubmed
pubmed-article:9086129pubmed:authorpubmed-author:RezzaGGlld:pubmed
pubmed-article:9086129pubmed:authorpubmed-author:PhillipsA NANlld:pubmed
pubmed-article:9086129pubmed:authorpubmed-author:PezzottiPPlld:pubmed
pubmed-article:9086129pubmed:authorpubmed-author:SabinC ACAlld:pubmed
pubmed-article:9086129pubmed:authorpubmed-author:LepriA CAClld:pubmed
pubmed-article:9086129pubmed:authorpubmed-author:EnglandP DPDlld:pubmed
pubmed-article:9086129pubmed:issnTypePrintlld:pubmed
pubmed-article:9086129pubmed:volume175lld:pubmed
pubmed-article:9086129pubmed:ownerNLMlld:pubmed
pubmed-article:9086129pubmed:authorsCompleteYlld:pubmed
pubmed-article:9086129pubmed:pagination775-80lld:pubmed
pubmed-article:9086129pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:9086129pubmed:meshHeadingpubmed-meshheading:9086129-...lld:pubmed
pubmed-article:9086129pubmed:meshHeadingpubmed-meshheading:9086129-...lld:pubmed
pubmed-article:9086129pubmed:meshHeadingpubmed-meshheading:9086129-...lld:pubmed
pubmed-article:9086129pubmed:year1997lld:pubmed
pubmed-article:9086129pubmed:articleTitleIs there a general tendency for CD4 lymphocyte decline to speed up during human immunodeficiency virus infection? Evidence from the Italian Seroconversion Study.lld:pubmed
pubmed-article:9086129pubmed:affiliationDepartment of Primary Care and Population Sciences, Royal Free Hospital, London, United Kingdom.lld:pubmed
pubmed-article:9086129pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9086129pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9086129lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9086129lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9086129lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9086129lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9086129lld:pubmed